Malaria Vaccine: Pfs25-Pvs25
$672,456ZIAFY2013AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications, trials & patents
Paper 39127706Paper 37100721Paper 37061547Paper 36808125Paper 35915227Paper 35895391Paper 33824913Paper 33741942Paper 32709983Paper 30061051Paper 29982707Paper 29522056Paper 28722588Paper 28719292Paper 27432885Paper 26590432Paper 26428458Paper 26324116Paper 26003037Paper 24737801Paper 20434549Paper 20080619Paper 18612426Paper 17190797
Abstract
The Pfs25-Pfs25 conjugate vaccine collaboration was inactivated due clinical hold of an IND filed with FDA, and due to personnel change at NICHD. In order to develop transmission blocking vaccine against P. vivax parasite, LMIV started projects to conjugate Pvs25 and Pvs230, orthologous proteins of transmission blocking vaccine candidates Pfs25 and Pfs230 being evaluated at LMIV, to protein carriers. The conjugates are being evaluate animal studies for immune enhancement and the antisera are being evaluated for transmission blocking activities in mosquitoes.
View original record on NIH RePORTER →